Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 361 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Overactive Bladder Clear all
Completed Phase 4 Interventional Results available

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial

NCT00863551
View directory record Official record
Conditions
Elderly, Pharmacokinetics, Overactive Bladder
Interventions
Trospium Chloride
Drug
Lead sponsor
Allergan
Industry
Eligibility
65 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2016 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Percutaneous Nerve Evaluation With Fluoroscopy Versus Without

NCT02677753
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence, Fecal Incontinence
Interventions
Fluoroscopy
Radiation
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 4 Interventional Results available

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial

NCT01178827
View directory record Official record
Conditions
Overactive Bladder
Interventions
trospium chloride, oxybutynin IR, oxybutynin IR placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 26, 2016 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Not applicable Interventional

Ease of Use Study of the FemPulse System

NCT06885099
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
FemPulse System
Device
Lead sponsor
FemPulse Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Implantable Tibial Neuromodulation (TITAN 1) Feasibility Study

NCT04873271
View directory record Official record
Conditions
Overactive Bladder
Interventions
Medtronic Implantable Tibial Neuromodulation (TNM) System
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
7
States / cities
Marietta, Georgia • Englewood, New Jersey • Hamlet, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 4 Interventional Results available

Validation of a Real-time Urodynamic Measure of Urinary Urgency

NCT00909428
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Solifenacin Succinate
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Combined Behavioral and Drug Treatment of Overactive Bladder in Men

NCT01175382
View directory record Official record
Conditions
Overactive Bladder, Lower Urinary Tract Symptoms
Interventions
Behavioral training, Tolterodine + tamsulosin, Combined Behavioral + Drug Therapy
Behavioral · Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older · Male only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Birmingham, Alabama • Atlanta, Georgia • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder

NCT03109379
View directory record Official record
Conditions
Idiopathic Overactive Bladder With Urinary Incontinence
Interventions
Trospium-Releasing Intravesical System (TAR-302-5018)
Drug
Lead sponsor
Taris Biomedical LLC
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
12
States / cities
Tucson, Arizona • San Diego, California • Pompano Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Not applicable Interventional Results available

eCoin for OAB Feasibility Follow-on Study

NCT03655054
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
Interventions
eCoin Tibial Nerve Stimulation
Device
Lead sponsor
Valencia Technologies Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Newport Beach, California • Waterloo, Iowa • Greensboro, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 20, 2026, 2:23 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A Study of Transcutaneous Electrical Nerve Stimulation for Overactive Bladder

NCT02922842
View directory record Official record
Conditions
Urge Incontinence, Overactive Bladder
Interventions
Transcutaneous Electrical Nerve Stimulation
Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 20, 2026, 2:23 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Premarin Versus Toviaz for Treatment of Overactive Bladder

NCT01613170
View directory record Official record
Conditions
Overactive Bladder
Interventions
Toviaz, Premarin, Placebo cream
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
30 Years to 100 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 3 Interventional

Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms

NCT00463541
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
solifenacin succinate
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
198
States / cities
Bay Minette, Alabama • Birmingham, Alabama • Decatur, Alabama + 171 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 20, 2026, 2:23 PM EDT
Terminated Not applicable Interventional Results available

Effectiveness of Bilateral PTNS Compared to Unilateral PTNS for the Treatment of Overactive Bladder/Urge Incontinence

NCT03535857
View directory record Official record
Conditions
Overactive Bladder Syndrome, Urinary Incontinence, Urge
Interventions
PTNS
Device
Lead sponsor
Gnankang Sarah Napoe
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 20, 2026, 2:23 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Practice-Based Intervention To Improve Care for a Diverse Population Of Women With Urinary Incontinence

NCT05534412
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Academic Detailing, Electronic Clinical Decision Support, APP Co-management, Electronic Referral
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
4
States / cities
La Jolla, California • Los Angeles, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects

NCT00902187
View directory record Official record
Conditions
Treatment of Overactive Bladder
Interventions
Fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Not applicable Interventional Results available

Posterior Tibial Nerve Stimulation's Effectiveness in UI Frequency in Overactive Patients in Home

NCT03595215
View directory record Official record
Conditions
Overactive Bladder
Interventions
TENS
Device
Lead sponsor
Theranova, L.L.C.
Industry
Eligibility
55 Years to 100 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 3 Interventional Results available

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00688688
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Tolterodine, Placebo to Mirabegron, Placebo to Tolterodine
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
106
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 96 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 3 Interventional Results available

Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.

NCT04534491
View directory record Official record
Conditions
Overactive Bladder
Interventions
Oxybutynin (Oxytrol, BAY839380)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Saint Joseph, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)

NCT03594058
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
1,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
77
States / cities
Birmingham, Alabama • Guntersville, Alabama • Saraland, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

TEST-ON - Does iStim Reduce Urinary Urgency?

NCT04957524
View directory record Official record
Conditions
Overactive Bladder, Urgency-frequency Syndrome, Urinary Frequency More Than Once at Night
Interventions
iStim TENS unit and Transvaginal Probe
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder

NCT00685113
View directory record Official record
Conditions
Overactive Bladder
Interventions
DR-3001, Placebo
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
81
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

BE Technologies Mobile Uroflowmetry Validation Study

NCT04599283
View directory record Official record
Conditions
BPH, BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms, BPH Without Urinary Obstruction, BPH Without Urinary Obstruction With Other Lower Urinary Tract Symptoms, Lower Urinary Tract Symptoms, Overactive Bladder, Overactive Bladder Syndrome, Urinary Obstruction, Urinary Incontinence, Urge
Interventions
MenHealth Uroflowmeter
Device
Lead sponsor
BE Technologies Inc
Industry
Eligibility
18 Years to 90 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 20, 2026, 2:23 PM EDT
Terminated Phase 4 Interventional Results available

Tetra-NIRS Clinical Study

NCT00871975
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Overactive Bladder
Interventions
Urodynamics + TETRA - NIRS
Device
Lead sponsor
Laborie Medical Technologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 20, 2026, 2:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder

NCT00501267
View directory record Official record
Conditions
Overactive Bladder
Interventions
solabegron and oxybutynin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 20, 2026, 2:23 PM EDT